AgeX Therapeutics, Inc.

67 articles with AgeX Therapeutics, Inc.

• AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

  9/9/2020

  AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th

• AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/14/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a rese

• AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

  6/16/2020

  Allows industry and academia access to cGMP-grade, NIH-registered AgeX ESI human pluripotent stem cells for development of cellular therapeutics AgeX ESI cell lines are among only a few pluripotent stem cell lines from which derived cell therapy candidates have been granted FDA IND clearance to begin human trials Pluristyx will manufacture, market, and distribute Ready-to-Use™ and Ready-to-Differentiate™ ESI stem cell lines vialed and frozen o

• AgeX Therapeutics Receives Stock Exchange Deficiency Letter

  6/5/2020

  AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that Age

• AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

  6/2/2020

  Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis, to be considered for further development in COVID19 and ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053

• AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A

  5/29/2020

  Sernova to utilize AgeX’s UniverCyte TM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell Pouch TM Platform ALAMEDA, Calif. & LONDON, Ontario--( BUSINESS WIRE )-- AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine th

• AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer

  5/21/2020

  AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer. Ms. Park replaces Russell Skibsted who served in that role since the Company was organized in 2017. Andrea Park served as our Vice

• AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

  5/14/2020

  AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.

• AgeX Therapeutics Announces Reduction in Projected Cash Expenditures

  5/1/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic,

• AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update

  3/30/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and year-end results for 2019.

• AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

  3/20/2020

  AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) th

• AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells

  2/28/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a new paper co-authored by two AgeX scientists that could lead to new insights into the fundamental mechanisms of aging and why super-centenarians not only live the longest, but also experience extraordinary healthspans; an extension of the healthy years of life that compresses morbidity to a very short period near the end of life.

• AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders

  2/3/2020

  Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform

• AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

  1/29/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeX’s HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

• AgeX Therapeutics to Participate at Four Conferences in January 2020

  1/14/2020

  AgeX Therapeutics, Inc. announced that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference, January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.

• AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.

  12/26/2019

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced the drawdown of a $1.3 million tranche of financing pursuant to its unsecured loan facility from Juvenescence Limited.

• AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

  12/10/2019

  AgeX Therapeutics, Inc. and Lineage Cell Therapeutics, Inc., announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem cells.

• AgeX Therapeutics Issues Year-End Letter to Shareholders

  12/9/2019

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress made in AgeX’s first year as a public company, as well as current initiatives and future plans.

• AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/14/2019

  Advanced GMP-compliant manufacturing capability

• AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform

  10/30/2019

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine